Expression of IP-10 related to angiogenesis in uterine cervical cancers

被引：41

作者：

Sato, E. ^{[1
]}

Fujimoto, J. ^{[1
]}

Toyoki, H. ^{[1
]}

Sakaguchi, H. ^{[1
]}

Alam, S. M. ^{[1
]}

Jahan, I. ^{[1
]}

Tamaya, T. ^{[1
]}

机构：

[1] Gifu Univ, Sch Med, Dept Obstet & Gynecol, Gifu 5011194, Japan

来源：

BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 11期

关键词：

IP-10; VEGF; angiogenesis; angiogenic inhibitor; uterine cervical cancer;

D O I：

10.1038/sj.bjc.6603790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is essential for development, growth and advancement of solid tumours. Interferon-gamma-inducible protein 10 (IP-10) regulates lymphocyte chemotaxis, mediates vascular pericyte proliferation and acts as an angiostatic agent, thus inhibiting tumour growth. This prompted us to study the clinical implications of IP-10 expression related to angiogenesis in uterine cervical cancers. The levels of IP-10 decreased with advancement, and the prognosis of the 30 patients with low IP-10 expression in uterine cervical cancers was poor (66%), whereas the 24-month survival rate of the other patients with high IP-10 expression was 90%. Furthermore, IP-10 levels significantly reverse-correlated with vascular endothelial growth factor (VEGF) levels in uterine cervical cancers. Interferon-gamma-inducible protein 10 might work on suppression of angiogenesis associated with VEGF in advancement, and can be recognised as a prognostic indicator. Furthermore, IP-10 activation might be effective on the suppression of regrowth or recurrence after intensive treatment for advanced cervical cancers.

引用

页码：1735 / 1739

页数：5

共 38 条

[21] Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers [J].

Fujimoto, J ;

Toyoki, H ;

Sato, E ;

Sakaguchi, H ;

Tamaya, T .

BRITISH JOURNAL OF CANCER, 2004, 91 (03) :466-469

[22] Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers [J].

Fujimoto, J ;

Aoki, I ;

Toyoki, H ;

Khatun, S ;

Tamaya, T .

ANNALS OF ONCOLOGY, 2002, 13 (10) :1598-1604

[23] Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers [J].

Fujimoto, J ;

Ichigo, S ;

Sakaguchi, H ;

Hirose, R ;

Tamaya, T .

CANCER LETTERS, 1998, 130 (1-2) :115-120

[24]

Fujimoto J, 1995, INVAS METAST, V15, P203

[25] Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers [J].

Fujimoto, J ;

Sakaguchi, H ;

Aoki, I ;

Khatun, S ;

Tamaya, T .

BRITISH JOURNAL OF CANCER, 2001, 85 (03) :313-316

[26] Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers [J].

Fujimoto, J ;

Ichigo, S ;

Hirose, R ;

Sakaguchi, H ;

Tamaya, T .

CANCER LETTERS, 1998, 134 (01) :15-22

[27] Evaluation of Na+ active transport and morphological changes for Bioartificial renal tubule cell device using Madin-Darby canine kidney cells [J].

Fujita, Y ;

Kakuta, T ;

Asano, M ;

Itoh, J ;

Sakabe, K ;

Tokimasa, T ;

Saito, A .

TISSUE ENGINEERING, 2002, 8 (01) :13-24

[28] TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques [J].

Gottlieb, AB ;

Chamian, F ;

Masud, S ;

Cardinale, I ;

Abello, MV ;

Lowes, MA ;

Chen, F ;

Magliocco, M ;

Krueger, JG .

JOURNAL OF IMMUNOLOGY, 2005, 175 (04) :2721-2729

[29]

Keane MP, 1997, J IMMUNOL, V159, P1437

[30] An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4 [J].

Lasagni, L ;

Francalanci, M ;

Annunziato, F ;

Lazzeri, E ;

Giannini, S ;

Cosmi, L ;

Sagrinati, C ;

Mazzinghi, B ;

Orlando, C ;

Maggi, E ;

Marra, F ;

Romagnani, S ;

Serio, M ;

Romagnani, P .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (11) :1537-1549

← 1 2 3 4 →